title: Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profiling.
abstract: OBJECTIVE
  Malignant epithelial ovarian cancer effusions are important in disease dissemination and clinical outcome. The identification of biochemical events active in effusions may improve our identification and application of targeted therapeutics.
  
  
  METHODS
  Archival effusion samples for which outcome information was known were studied. Clinical variables were comparable between these groups. Two cohorts of patients with malignant effusion were assessed: those with effusion at presentation (Tap1) or at first recurrence (Tap2). Expression and activated fraction of selected signaling proteins were quantitated on serial protein microarrays using validated antibodies. Proteomic results and clinical variables were analyzed by univariate analysis followed by Cox proportional hazards model analysis.
  
  
  RESULTS
  Malignant effusions (>80% malignant cells) were distinguished from benign effusions by higher expression of AKT, activated extracellular signal-regulated kinase, activated (P < or = 0.001) and total cAMP-responsive element binding protein (P = 0.01), and JNK (P = 0.03). Malignant pleural effusions could not be differentiated from ascites by signaling profiles. Both had signal expression clusters for survival, proliferation and metastasis, and injury pathways. Cox proportional hazards model analysis revealed high p38 and pEGFR/EGFR ratio as jointly associated with poor survival in Tap1 cases (both P < or = 0.002). Phospho-JNK quantity was associated with worse outcome in Tap2 patients (P = 0.004), when taking other factors into consideration.
  
  
  CONCLUSIONS
  Proliferation, survival, and apoptosis signaling dysregulation can be identified in ovarian cancer effusion samples. Biochemical characterization of clinical effusions may provide either predictive and/or correlative information on patient outcome from which to further understand the mechanisms of effusion development and target clinical intervention.
authors.affiliation: Molecular Signaling Section, Laboratory of Pathology, National Cancer Institute, Bethesda Maryland 20892, USA
authors.forename: Ben
authors.initials: B
authors.lastname: Davidson
authors.forename: Virginia
authors.initials: V
authors.lastname: Espina
authors.forename: Seth M
authors.initials: SM
authors.lastname: Steinberg
authors.forename: Vivi Ann
authors.initials: VA
authors.lastname: Flørenes
authors.forename: Lance A
authors.initials: LA
authors.lastname: Liotta
authors.forename: Gunnar B
authors.initials: GB
authors.lastname: Kristensen
authors.forename: Claes G
authors.initials: CG
authors.lastname: Tropé
authors.forename: Aasmund
authors.initials: A
authors.lastname: Berner
authors.forename: Elise C
authors.initials: EC
authors.lastname: Kohn
mesh_terms: D017209:Apoptosis / Q000502:physiology; D001202:Ascitic Fluid / Q000737:chemistry* / Q000378:metabolism; D049109:Cell Proliferation; D002470:Cell Survival / Q000502:physiology; D015331:Cohort Studies; D018450:Disease Progression; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000175:diagnosis* / Q000378:metabolism; D016066:Pleural Effusion, Malignant / Q000737:chemistry* / Q000378:metabolism; D011379:Prognosis; D040901:Proteomics; D012189:Retrospective Studies; D015398:Signal Transduction / Q000502:physiology; D015996:Survival Rate